Aidoc’s solution for flagging and prioritizing pulmonary embolisms is now commercially available in Europe

The global market for transcatheter treatment of the mitral and aortic valves is expected to double over the next five years, according to a new report from BCC Research. The industry analysis projects an increase from $4 billion in 2018 to $8 billion in 2023, at a compound annual growth rate (CAGR) of 14.8 percent.

A small-scale study out of Germany has concluded thrombectomy—an already proven treatment for large intracranial vessel occlusions in adults—is also safe in children.

A new matchstick-sized continuous glucose monitor (CGM) can be implanted under the skin, allowing diabetics to track their blood sugar without the inconvenience of finger pricks and patches, according to a CBS report.

Two of Medtronic’s drug-eluting stents (DES)—the Resolute Onyx and the Resolute Integrity—have been granted FDA approval to treat coronary artery disease patients with chronic total occlusion (CTO), the company announced Feb. 26.

Women see worse outcomes than men after thoracic aortic surgery requiring hypothermic circulatory arrest (HCA), researchers reported in the Feb. 26 edition of Circulation.

When endovascular thrombectomy procedures for acute ischemic stroke take more than an hour or require more than three attempts to remove the clot, outcomes significantly worsen, according to a study published Feb. 25 in the Journal of the American College of Cardiology.

The FDA issued a safety alert Feb. 25 warning that a 10 mg, twice-daily dose of tofacitinib—sold under the brand names Xeljanz and Xeljanz XR—has been linked to an increased risk of pulmonary embolism and death in patients with rheumatoid arthritis. That dose is only approved for patients with ulcerative colitis, the agency said.